Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19
COVID-19 caused by the novel SARS-CoV-2 has been declared a pandemic by the WHO is causing havoc across the entire world. As of May end, about 6 million people have been affected, and 367 166 have died from COVID-19. Recent studies suggest that the SARS-CoV-2 genome shares about 80% similarity with...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Elsevier Inc
2020
|
| Subjects: |
| _version_ | 1796865466315046912 |
|---|---|
| author | Faheem, Faheem Kumar, Banoth Karan Sekhar, Kondapalli Venkata Gowri Chandra Kunjiappan, Selvaraj Jamalis, Joazaizulfazli Balana Fouce, Rafael Tekwani, Babu L. Sankaranarayanan, Murugesan |
| author_facet | Faheem, Faheem Kumar, Banoth Karan Sekhar, Kondapalli Venkata Gowri Chandra Kunjiappan, Selvaraj Jamalis, Joazaizulfazli Balana Fouce, Rafael Tekwani, Babu L. Sankaranarayanan, Murugesan |
| author_sort | Faheem, Faheem |
| collection | ePrints |
| description | COVID-19 caused by the novel SARS-CoV-2 has been declared a pandemic by the WHO is causing havoc across the entire world. As of May end, about 6 million people have been affected, and 367 166 have died from COVID-19. Recent studies suggest that the SARS-CoV-2 genome shares about 80% similarity with the SARS-CoV-1 while their protein RNA dependent RNA polymerase (RdRp) shares 96% sequence similarity. Remdesivir, an RdRp inhibitor, exhibited potent activity against SARS-CoV-2 in vitro. 3-Chymotrypsin like protease (also known as Mpro) and papain-like protease, have emerged as the potential therapeutic targets for drug discovery against coronaviruses owing to their crucial role in viral entry and host-cell invasion. Crystal structures of therapeutically important SARS-CoV-2 target proteins, namely, RdRp, Mpro, endoribonuclease Nsp15/NendoU and receptor binding domain of CoV-2 spike protein has been resolved, which have facilitated the structure-based design and discovery of new inhibitors. Furthermore, studies have indicated that the spike proteins of SARS-CoV-2 use the Angiotensin Converting Enzyme-2 (ACE-2) receptor for its attachment similar to SARS-CoV-1, which is followed by priming of spike protein by Transmembrane protease serine 2 (TMPRSS2) which can be targeted by a proven inhibitor of TMPRSS2, camostat. The current treatment strategy includes repurposing of existing drugs that were found to be effective against other RNA viruses like SARS, MERS, and Ebola. This review presents a critical analysis of druggable targets of SARS CoV-2, new drug discovery, development, and treatment opportunities for COVID-19. |
| first_indexed | 2024-03-05T20:57:26Z |
| format | Article |
| id | utm.eprints-92651 |
| institution | Universiti Teknologi Malaysia - ePrints |
| last_indexed | 2024-03-05T20:57:26Z |
| publishDate | 2020 |
| publisher | Elsevier Inc |
| record_format | dspace |
| spelling | utm.eprints-926512021-10-28T10:25:17Z http://eprints.utm.my/92651/ Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 Faheem, Faheem Kumar, Banoth Karan Sekhar, Kondapalli Venkata Gowri Chandra Kunjiappan, Selvaraj Jamalis, Joazaizulfazli Balana Fouce, Rafael Tekwani, Babu L. Sankaranarayanan, Murugesan QD Chemistry COVID-19 caused by the novel SARS-CoV-2 has been declared a pandemic by the WHO is causing havoc across the entire world. As of May end, about 6 million people have been affected, and 367 166 have died from COVID-19. Recent studies suggest that the SARS-CoV-2 genome shares about 80% similarity with the SARS-CoV-1 while their protein RNA dependent RNA polymerase (RdRp) shares 96% sequence similarity. Remdesivir, an RdRp inhibitor, exhibited potent activity against SARS-CoV-2 in vitro. 3-Chymotrypsin like protease (also known as Mpro) and papain-like protease, have emerged as the potential therapeutic targets for drug discovery against coronaviruses owing to their crucial role in viral entry and host-cell invasion. Crystal structures of therapeutically important SARS-CoV-2 target proteins, namely, RdRp, Mpro, endoribonuclease Nsp15/NendoU and receptor binding domain of CoV-2 spike protein has been resolved, which have facilitated the structure-based design and discovery of new inhibitors. Furthermore, studies have indicated that the spike proteins of SARS-CoV-2 use the Angiotensin Converting Enzyme-2 (ACE-2) receptor for its attachment similar to SARS-CoV-1, which is followed by priming of spike protein by Transmembrane protease serine 2 (TMPRSS2) which can be targeted by a proven inhibitor of TMPRSS2, camostat. The current treatment strategy includes repurposing of existing drugs that were found to be effective against other RNA viruses like SARS, MERS, and Ebola. This review presents a critical analysis of druggable targets of SARS CoV-2, new drug discovery, development, and treatment opportunities for COVID-19. Elsevier Inc 2020-11 Article PeerReviewed Faheem, Faheem and Kumar, Banoth Karan and Sekhar, Kondapalli Venkata Gowri Chandra and Kunjiappan, Selvaraj and Jamalis, Joazaizulfazli and Balana Fouce, Rafael and Tekwani, Babu L. and Sankaranarayanan, Murugesan (2020) Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. Bioorganic Chemistry, 104 . ISSN 0045-2068 http://dx.doi.org/10.1016/j.bioorg.2020.104269 DOI:10.1016/j.bioorg.2020.104269 |
| spellingShingle | QD Chemistry Faheem, Faheem Kumar, Banoth Karan Sekhar, Kondapalli Venkata Gowri Chandra Kunjiappan, Selvaraj Jamalis, Joazaizulfazli Balana Fouce, Rafael Tekwani, Babu L. Sankaranarayanan, Murugesan Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 |
| title | Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 |
| title_full | Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 |
| title_fullStr | Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 |
| title_full_unstemmed | Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 |
| title_short | Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19 |
| title_sort | druggable targets of sars cov 2 and treatment opportunities for covid 19 |
| topic | QD Chemistry |
| work_keys_str_mv | AT faheemfaheem druggabletargetsofsarscov2andtreatmentopportunitiesforcovid19 AT kumarbanothkaran druggabletargetsofsarscov2andtreatmentopportunitiesforcovid19 AT sekharkondapallivenkatagowrichandra druggabletargetsofsarscov2andtreatmentopportunitiesforcovid19 AT kunjiappanselvaraj druggabletargetsofsarscov2andtreatmentopportunitiesforcovid19 AT jamalisjoazaizulfazli druggabletargetsofsarscov2andtreatmentopportunitiesforcovid19 AT balanafoucerafael druggabletargetsofsarscov2andtreatmentopportunitiesforcovid19 AT tekwanibabul druggabletargetsofsarscov2andtreatmentopportunitiesforcovid19 AT sankaranarayananmurugesan druggabletargetsofsarscov2andtreatmentopportunitiesforcovid19 |